CVM
AMEXCel-Sci Corporation
News · 26 weeks41+400%
2026-03-012026-08-23
Mix2490d
- Other9(38%)
- Insider9(38%)
- SEC Filings5(21%)
- Offering1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Watson Robert Eugene4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERSEC Form 4 filed by Director Baillavoine Bruno Jean-Marie4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERSEC Form 4 filed by Senior Vice President Cipriano John4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Talor Eyal4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Prichep Patricia B4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Kersten Geert R4 - CEL SCI CORP (0000725363) (Issuer)
- SECCel-Sci Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CEL SCI CORP (0000725363) (Filer)
- PRCEL-SCI Reports Fiscal Third Quarter 2026 ResultsPeer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study Dual track commercialization strategy includes the global Confirmatory Registration study to commence enrollment in the U.S., Europe, Asia and South America for U.S. FDA approval, with a parallel process in Saudi Arabia for Breakthrough Designation which could make Multikine commercially available in the near term Signed key partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia CEL-SCI Corporation (NYSE:CVM) today reported f
- SECSEC Form 10-Q filed by Cel-Sci Corporation10-Q - CEL SCI CORP (0000725363) (Filer)
- PRCEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration StudyThe published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatment Study concludes Multikine represents the first neoadjuvant treatment in decades to demonstrate an overall survival benefit in biomarker-selected patients with locally advanced resectable oral cancer Multikine neoadjuvant treatment also demonstrated a statistically significant improvement in progression-free survival with a 49% reduction in the risk of disease progression in the same biomarker-selected patients CEL-SCI Corporation (NYSE:CVM) today announced the publication of its study, "A
- PRLeading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer PatientsPeer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory Registration Study CEL-SCI Corporation (NYSE:CVM) today announced that a manuscript highlighting the latest findings from its Phase 3 study titled "A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival in Oral Cancer Patients with Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role of Tumor PD-L1 Expression," has been accepted for publication in Oral Oncology, one of the world's leading peer-reviewed journals dedicated to head and neck cancer research and
- PRCEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerPatient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA CEL-SCI Corporation (NYSE:CVM) today announced it is launching its global Confirmatory Registration Study of
- SECSEC Form DEF 14A filed by Cel-Sci CorporationDEF 14A - CEL SCI CORP (0000725363) (Filer)
- INSIDERChief Scientific Officer Talor Eyal was granted 2,307 shares, increasing direct ownership by 33% to 9,318 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERChief Financial Officer Prichep Patricia B was granted 4,125 shares, increasing direct ownership by 31% to 17,489 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERChief Executive Officer Kersten Geert R was granted 5,192 shares, increasing direct ownership by 2% to 216,142 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- PRCEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer CareCeremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration Strategic partnership spans regulatory, marketing, distribution, and revenue sharing agreement for Multikine® in the treatment of head and neck cancer in Saudi Arabia with option to extend to Gulf Cooperation Council countries CEL-SCI Corporation (NYSE:CVM) today announced the successful conclusion of a formal signing ceremony with Saudi Amarox ("Amarox") during the BIO International Convention 2026 on June 22nd in San Diego, marking a significant step forward in U.S.–Saudi cooperation in healthcare innovation and oncology. This press release features multimedia. View t
- SECCel-Sci Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - CEL SCI CORP (0000725363) (Filer)
- PRCEL-SCI Announces Closing of OfferingCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $1.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $2.5 million.The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.ThinkEquity acted as the sole placement agent for the offering.The securities were offered and sold pursuant to a
- PRCEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry StrategyU.S. Confirmatory Registration Study expected to begin Summer 2026 Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of life Saudi partnership includes a 50%/50% net revenue share and supports potential patient access in one of the Middle East's largest oncology markets CEL-SCI Corporation (NYSE:CVM) today highlighted its dual-track strategy to bring Multikine® (Leukocyte Interleukin, Injection)* to patients with newly diagnosed locally advanced head and neck cancer through parallel regulatory initiatives in the U.S. and Saudi Arabia. The Company plans to commence its Confirmatory Registration
- SECSEC Form 424B5 filed by Cel-Sci Corporation424B5 - CEL SCI CORP (0000725363) (Filer)
- PRCEL-SCI Corporation Announces Pricing of OfferingCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at an offering price of $1.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and offering expenses, are expected to be $2.5 million. The offering is expected to close on June 16, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the proceeds for the continued development of Multikine*, general corporate purposes, and working capital. ThinkEquity is acting as the sole placement agent for the offering. Th
- PRCEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi ArabiaSaudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030 Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing & Opening Ceremonies Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets CEL-SCI Corporation (NYSE:CVM) today announced it will participate in a formal signing ceremony with Saudi Amarox ("Amarox") during the BIO International Convention 2026 in San Diego, California. The ceremony will mark an important milestone in advancing the previously announced strategic agreement between the companies focused on the commercialization an
- SECSEC Form RW filed by Cel-Sci CorporationRW - CEL SCI CORP (0000725363) (Filer)
- SECSEC Form RW filed by Cel-Sci CorporationRW - CEL SCI CORP (0000725363) (Filer)
CVM FAQ
6 questionsWhat does Cel-Sci Corporation do?
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC...Where does CVM stock trade?
Cel-Sci Corporation (CVM) is listed on AMEX.What sector and industry is CVM in?
Cel-Sci Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Cel-Sci Corporation go public?
Cel-Sci Corporation (CVM) completed its IPO in 1997.What companies are similar to CVM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare CVM side-by-side with any of them on Quantisnow.How can I track CVM on Quantisnow?
Quantisnow aggregates Cel-Sci Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CVM to receive live email and push alerts on every new disclosure.